WHO ICTRP trial

A research study to look at how semaglutide compared to placebo affects diabetic…

EUCTR2017-003619-20-GB · EU Clinical Trials Register · Authorised

Key facts

Trial ID EUCTR2017-003619-20-GB
Public title A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes
Scientific title Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes - FOCUS
Primary sponsor Novo Nordisk A/S
Registry EU Clinical Trials Register
Recruitment status Authorised
Study type Interventional clinical trial of medicinal product
Phase Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries Portugal;United States;Serbia;Slovakia;Spain;Israel;Russian Federation;United Kingdom;India;Czech Republic;European Union;Mexico;Canada;Brazil;Bulgaria;Latvia
Conditions Diabetes Mellitus, Type 2 MedDRA version: 21.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Interventions Trade Name: Ozempic® Pharmaceutical Form: Solution for injection INN or Proposed INN: semaglutide CAS Number: 910463-68-2 Other descriptive name: SEMAGLUTIDE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal…
Registration date Oct 12, 2018
Target size 1500
Secondary IDs NN9535-4352
Registry page clinicaltrialsregister.eu

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations